{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:35:01Z","timestamp":1759412101842,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.vaccine.2020.04.005","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T07:37:19Z","timestamp":1586763439000},"page":"3930-3933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A new strategy for preparing a tailored meningococcal ACWY conjugate vaccine for clinical testing"],"prefix":"10.1016","volume":"38","author":[{"given":"Alessio","family":"Moriconi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Onnis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Aggravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Parlati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Bufali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Cianetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Egan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Fragapane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malte","family":"Meppen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilena","family":"Paludi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4906-5644","authenticated-orcid":false,"given":"Francesco","family":"Berti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.04.005_b0005","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/14712598.2015.993375","article-title":"Glycoconjugate vaccines: an update","volume":"15","author":"Vella","year":"2015","journal-title":"Exp Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2020.04.005_b0010","doi-asserted-by":"crossref","unstructured":"Berti F. Multivalent meningococcal conjugate vaccines: chemical conjugation strategies used for the preparation of vaccines licensed or in clinical trials. ACS Books \u201cCarbohydrate-Based Vaccines: From Concept to Clinic\u201d 2018;1290: p. 123\u201337 [Chapter 6].","DOI":"10.1021\/bk-2018-1290.ch006"},{"issue":"10","key":"10.1016\/j.vaccine.2020.04.005_b0015","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S1473-3099(18)30400-6","article-title":"Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study","volume":"18","author":"Chen","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.04.005_b0030","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1517\/17460441.2011.609554","article-title":"The design of semi-synthetic and synthetic glycoconjugate vaccines","volume":"6","author":"Costantino","year":"2011","journal-title":"Exp Opin Drug Discov"},{"key":"10.1016\/j.vaccine.2020.04.005_b0035","doi-asserted-by":"crossref","unstructured":"Gudlavalleti SK, Datta AK, Tzeng YL, Noble C, Carlson RW, Stephens DS. The Neisseria meningitidis serogroup A capsular polysaccharide O-3 and O-4 acetyltransferase. J Biol Chem 2004;279, doi: 42765-73. 10.1074\/jbc.M313552200.","DOI":"10.1074\/jbc.M313552200"},{"key":"10.1016\/j.vaccine.2020.04.005_b0040","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.vaccine.2008.01.022","article-title":"Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases","volume":"26","author":"Bardotti","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.005_b0045","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1128\/IAI.70.7.3707-3713.2002","article-title":"Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses","volume":"70","author":"Berry","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.04.005_b0050","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.vaccine.2008.11.065","article-title":"Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa","volume":"27","author":"Lee","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.005_b0055","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1128\/CVI.00162-13","article-title":"Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years","volume":"20","author":"Lupisan","year":"2013","journal-title":"Clin Vacc Immunol"},{"key":"10.1016\/j.vaccine.2020.04.005_b0060","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1016\/j.vaccine.2017.03.066","article-title":"Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM197, DT and TT glycoconjugate vaccines","volume":"35","author":"Beresford","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.005_b0020","unstructured":"NCT03433482 - A study to investigate the safety and immunogenicity of different formulations of GSK Biologicals' meningococcal ACWY conjugate vaccine (GSK3536820A and Menveo) administered to healthy adolescents and young adults 10\u201340 years of age. <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03433482>."},{"key":"10.1016\/j.vaccine.2020.04.005_b0025","unstructured":"NCT03652610 - A study to investigate the safety and immunogenicity of different formulations of GSK Biologicals' meningococcal ACWY conjugate vaccine (GSK3536820A and Menveo) administered to healthy adults 18 to 40 years of age. <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03652610>."},{"key":"10.1016\/j.vaccine.2020.04.005_b0065","doi-asserted-by":"crossref","first-page":"12827","DOI":"10.1021\/acsomega.9b01678","article-title":"NMR assays for estimating the O-acetyl content of meningococcal polysaccharide serogroup A in quadrivalent conjugate vaccine formulation","volume":"4","author":"Martini","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.vaccine.2020.04.005_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aat4615","article-title":"Glycoconjugate vaccines: principles and mechanisms","volume":"10","author":"Rappuoli","year":"2018","journal-title":"Sci Transl Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20304631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20304631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:43:05Z","timestamp":1759401785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20304631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":14,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0264410X20304631"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.04.005","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new strategy for preparing a tailored meningococcal ACWY conjugate vaccine for clinical testing","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}